

In the Claims

Please cancel claims 16, 18, 21, 23, 29, 33, 37, 43, 50, 57, 61, 68, 72 and 80 without prejudice or disclaimer.

Please amend the claims as noted below. Applicant has submitted a new complete claim set marked up to show insertions and deletions by underlining and strikeouts, respectively.

1. (Canceled)
2. (Currently amended) An isolated HLA DRB1*15-binding peptide consisting of
the amino acid sequence set forth as SEQ ID NO:7, or a functional variant thereof consisting of one amino acid addition; or substitution ~~or deletion~~, and
0-10 amino acids added to either or both ends of the amino acid sequence set forth as SEQ ID NO:7, or the functional variant thereof consisting of one amino acid addition, substitution or deletion.
3. (Canceled)
4. (Canceled)
5. (Previously presented) The isolated HLA DRB1*15-binding peptide of claim 2 wherein the isolated peptide comprises an endosomal targeting signal.
6. (Canceled)
7. (Previously presented) The isolated HLA DRB1*15-binding peptide of claim 2 wherein the isolated peptide is non-hydrolyzable.
8. (Canceled)

RECEIVED
JUL 3 1 2003
TECH CENTER 1600/2900

9. (Currently amended) A composition comprising an isolated MAGE-A1 HLA class I-binding peptide and an isolated MAGE-A1 HLA DRB1*15-binding peptide, wherein the isolated HLA class II-binding peptide consists of

the amino acid sequence set forth as SEQ ID NO:7, or a functional variant thereof consisting of one amino acid addition, substitution or deletion, and

0-10 amino acids added to either or both ends of the amino acid sequence set forth as SEQ ID NO:7, or the functional variant thereof consisting of one amino acid addition, substitution or deletion, and

wherein the HLA class I-binding peptide and the HLA class II-binding peptide are separate isolated peptides.

10-13 (Canceled)

14. (Previously presented) The composition of claim 9 wherein the isolated MAGE-A1 HLA DRB1*15-binding peptide comprises an endosomal targeting signal.

15.-75. (Canceled)

76. (Currently amended) The isolated HLA DRB1*15-binding peptide of claim 2 wherein the isolated peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:7, or a functional variant thereof consisting of one amino acid addition, or substitution ~~or~~ deletion.

77. (Previously presented) The isolated HLA DRB1*15-binding peptide of claim 2 wherein the isolated peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:7.

78. (Previously presented) The isolated HLA DRB1*15-binding peptide of claim 5 wherein the endosomal targeting signal comprises an endosomal targeting portion of human invariant chain II or LAMP-1.

79. (Previously presented) The isolated HLA DRB1*15-binding peptide of claim 7 wherein the isolated peptide is selected from the group consisting of peptides comprising D-amino acids, peptides comprising a -psi[CH₂NH]-reduced amide peptide bond, peptides comprising a -psi[COCH₂]-ketomethylene peptide bond, peptides comprising a -psi[CH(CN)NH]-(cyanomethylene)amino peptide bond, peptides comprising a -psi[CH₂CH(OH)]-hydroxyethylene peptide bond, peptides comprising a -psi[CH₂O]-peptide bond, and peptides comprising a -psi[CH₂S]-thiomethylene peptide bond.

80. (Canceled)

81. (Previously presented) The composition of claim 9 wherein the isolated MAGE-A1 HLA DRB1*15-binding peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:7, or a functional variant thereof consisting of one amino acid addition, substitution or deletion.

82. (Previously presented) The composition of claim 9 wherein the isolated MAGE-A1 HLA DRB1*15-binding peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:7.

83. (Previously presented) The composition of claim 14 wherein the endosomal targeting signal comprises an endosomal targeting portion of human invariant chain II or LAMP-1.

84. (New) A composition comprising
an isolated MAGE-A1 HLA DRB1*15-binding peptide comprising the amino acid sequence set forth as SEQ ID NO:7, or a functional variant thereof consisting of one amino acid addition, substitution or deletion, and
a non-MAGE-A1 HLA class I-binding peptide.

85. (New) The composition of claim 84 wherein the non-MAGE-A1 HLA class I-binding peptide and the MAGE-A1 HLA DRB1*15-binding peptide are combined as a polytope polypeptide.

86. (New) The composition of claim 84 wherein the isolated MAGE-A1 HLA DRB1*15-binding peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:7, or a functional variant thereof consisting of one amino acid addition, substitution or deletion.

87. (New) The composition of claim 84 wherein the isolated MAGE-A1 HLA DRB1*15-binding peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:7.